Albumin/interferon alpha 2A fusion protein(Tianjin PuYing Biotechnology)

Using standard dose of Pegasys (180μg/week) as positive control, chronic hepatitis B patients were selected as subjects to explore and evaluate the tolerance and safety of multiple subcutaneous injections of recombinant human serum albumin/interferon α2a fusion protein injection. At the same time, the pharmacokinetics and preliminary efficacy of the drug after single and multiple administrations in patients with chronic hepatitis B were studied, and the effective dose was explored to provide a basis for the formulation of safe and effective dosing regimens for Phase II and III clinical trials.